Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful (Chinese: 科维福; pinyin: Kēwéifú), is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences .
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | Covidful (Chinese: 科维福; pinyin: Kēwéifú) |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
Identifiers | |
DrugBank |
Clinical trials edit
In May 2020, Covidful started phase I/II clinical trial with 942 participants in China.[2]
In January 2021, Covidful started phase III clinical trials with 34,020 from Brazil and Malaysia.[3]
Authorizations edit
Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
On 9 June 2021, The vaccine has been approved by the Chinese authorities.[1]
References edit
- ^ a b Liu R, Woo R (9 June 2021). "China builds new plant for IMBCAMS COVID-19 vaccine -state media". Reuters. Retrieved 15 June 2021.
- ^ Clinical trial number NCT04412538 for "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov
- ^ Clinical trial number NCT04659239 for "The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19" at ClinicalTrials.gov